ORX750 Clinical Trials (2026): 2 Studies for Idiopathic Hypersomnia & Narcolepsy Type 1

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2 ORX750 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Idiopathic Hypersomnia & Narcolepsy Type 1) and 338 total planned enrollment. 2 ORX750 clinical trials are actively recruiting at 48 U.S. sites across 14 states. Most recent activity: NCT06752668 (Dec 2026).

Where to Participate: All ORX750 Trial Sites in the U.S. (48 sites across 14 states)

Every actively recruiting ORX750trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALAuburn, alabamaAuburn36832NCT07096674Map
ALAuburn, AlabamaAuburn36832NCT06752668Map
AZChandler, ArizonaChandler85224NCT06752668Map
AZScottsdale, ArizonaScottsdale85253NCT06752668Map
CALong Beach, CaliforniaLong Beach90805NCT06752668Map
CASanta Ana, CaliforniaSanta Ana92705NCT06752668Map
CASanta Ana, CaliforniaSanta Ana92705NCT07096674Map
FLBrandon, FloridaBrandon33511NCT06752668Map
FLMiami, FloridaMiami33155NCT06752668Map
FLMiami, FloridaMiami33176NCT06752668Map
FLMiami, FloridaMiami33176NCT07096674Map
FLOrlando, FLOrlando32807NCT06752668Map
FLOrlando, FloridaOrlando32807NCT07096674Map
FLWinter Park, FLWinter Park32789NCT07096674Map
FLWinter Park, FloridaWinter Park32789NCT06752668Map
GAAtlanta, GeorgiaAtlanta30281NCT06752668Map
GAAtlanta, GeorgiaAtlanta30328NCT06752668Map
GAAtlanta, GeorgiaAtlanta30328NCT07096674Map
GAStockbridge, GAAtlanta30281NCT07096674Map
GARiverdale, GeorgiaRiverdale30274NCT06752668Map
LANew Orleans, LouisianaNew Orleans70127NCT06752668Map
MANewton, MassachusettsNewton02459NCT06752668Map
MISouthfield, MichiganSouthfield48075NCT06752668Map
MISterling Heights, MichiganSterling Heights48314NCT06752668Map
MISterling Heights, MichiganSterling Heights48314NCT07096674Map
NVHendersen, NavadaHenderson89052NCT07096674Map
NVHenderson, NevadaHenderson89052NCT06752668Map
NVHenderson, NevadaHenderson89052NCT07096674Map
NCDenver, North CarolinaDenver28037NCT06752668Map
NCDenver, North CarolinaDenver28037NCT07096674Map
NCHuntersville, North CarolinaHuntersville28078NCT06752668Map
NCHuntersville, North CarolinaHuntersville28070NCT07096674Map
OHCincinnati, OhioCincinnati45245NCT06752668Map
OHCincinnati, OhioCincinnati45245NCT07096674Map
OHCleveland, OHCleveland44106NCT06752668Map
OHDublinDublin43017NCT07096674Map
OHDublin, OhioDublin43017NCT06752668Map
PAAbington, PennsylvaniaAbington19046NCT07096674Map
PAWillow Grove, PennsylvaniaWillow Grove19090NCT06752668Map
PAWillow Grove, PennsylvaniaWillow Grove19090NCT07096674Map
SCColumbia, South CarolinaColumbia29201NCT06752668Map
SCNorth Charleston, South CarolinaNorth Charleston29406NCT06752668Map
SCNorth Charleston, South CarolinaNorth Charleston29406-9196NCT07096674Map
TXAustin, TexasAustin78731NCT06752668Map
TXAustin, TexasAustin30328NCT07096674Map
TXEl Paso, TexasEl Paso79912NCT07096674Map
TXEl Paso, TXEl Paso79912NCT06752668Map
TXSan Antonio, TexasSan Antonio78229NCT06752668Map

ORX750 clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P222

Recruiting ORX750 clinical trials (2)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06752668CRYSTAL-1A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaP2Narcolepsy Type 1248Dec 2024
NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaP2Narcolepsy Type 190Aug 2025

ORX750 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
CRYSTAL-1NCT06752668P2recruitingNarcolepsy Type 1248—

All ORX750 trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06752668CRYSTAL-1A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaP2recruiting248Centessa Pharmaceuticals (UK) LimitedDec 2024
NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaP2recruiting90Centessa Pharmaceuticals (UK) LimitedAug 2025

ORX750 clinical trials: frequently asked questions

How many ORX750 clinical trials are there?
2 ORX750 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
Are ORX750 clinical trials recruiting in 2026?
Yes — 2 ORX750 trials are actively recruiting in 2026, with 48 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
What conditions is ORX750 being studied for?
ORX750 is being studied for Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2. The trials are grouped by indication on this page.
What phase is ORX750 in?
ORX750 clinical trials span 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors ORX750 clinical trials?
The lead sponsor across the most ORX750 trials is Centessa Pharmaceuticals (UK) Limited. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ORX750as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

ORX750 overview